Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to tame rare blood cancers

NCT ID NCT05936359

Ongoing Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called INCA033989, alone or with an existing drug ruxolitinib, in 225 people with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check safety and find the best dose. Participants must have a specific genetic mutation (CALR) and be willing to have bone marrow tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
INCA033989 and ruxolitinib
What this could lead to
If successful, this could lead to a new treatment option for myeloproliferative neoplasms, potentially improving symptom control and reducing spleen size.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is not yet known if the drug works. Side effects and limited effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOPROLIFERATIVE NEOPLASMS

Contacts and locations

Locations

  • Aou Policlinico S. Orsola-Malpighi

    Bologna, 40138, Italy

  • Azienda Ospedaliero-Universitaria Careggi (Aouc)

    Florence, 50134, Italy

  • Chu Nimes

    Nîmes, 30029, France

  • Fondazione Irccs Ca Granda Ospedale Maggiore

    Milan, 20122, Italy

  • Guys and St Thomas Nhs Foundation Trust

    London, SE1 9RT, United Kingdom

  • Hopital Maisonneuve-Rosemont, Montreal, Qc

    Montreal, Quebec, H1T 2M4, Canada

  • Hospital Saint Louis

    Paris, 75010, France

  • Hospital Universitari I Politecnic La Fe

    Valencia, 46026, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Institut Bergonie

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Kagoshima University Hospital

    Kagoshima, 890-8520, Japan

  • Mie University Hospital

    Tsu, 514-0001, Japan

  • National Cancer Center Hospital East

    Chiba-ken, 277-0882, Japan

  • Nippon Medical School Hospital

    Tokyo, 113-8603, Japan

  • Osaka Metropolitan University Hospital

    Osaka, 545-8586, Japan

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, 03000, Australia

  • Princess Margaret Cancer Center

    Toronto, Ontario, M5G 2M9, Canada

  • Royal Adelaide Hospital

    Adelaide, South Australia, 05000, Australia

  • Royal Brisbane and Women'S Hospital

    Herston, Queensland, 04029, Australia

  • Sjaellands Universitetshospital

    Roskilde, 04000, Denmark

  • The Alfred Hospital

    Melbourne, Victoria, 03004, Australia

  • The Christie Nhs Foundation Trust Uk

    Manchester, M20 4BV, United Kingdom

  • Universitatsklinikum Halle (Saale)

    Halle, 06120, Germany

  • University Medical Center Rwth Aachen

    Aachen, 52074, Germany

  • University of Oxford

    Oxford, OX3 7LE, United Kingdom

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

  • Vejle Hospital

    Vejle, 07100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.